Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Justice

###### Drug Enforcement Administration

                    On August 30, 2023, the Drug Enforcement Administration (DEA or Government) issued an Order to Show Cause (OSC) to Theodore S. Wright Jr., M.D., of Chicago, Illinois (Registrant). Request for Final Agency Action (RFAA), Exhibit (RFAAX) 1, at 1, 3. The OSC proposed the revocation of Registrant's Certificate of Registration No. AW2016651, alleging that Registrant's registration should be revoked because Registrant is “currently without authority to prescribe, administer, dispense, or otherwise handle controlled substances in the State of Illinois, the state in which [he is] registered with DEA.”                     *Id.*                     at 1-2 (citing 21 U.S.C. 824(a)(3)).                

                    The OSC notified Registrant of his right to file with DEA a written request for hearing, and that if he failed to file such a request, he would be deemed to have waived his right to a hearing and be in default.                     *Id.*                     at 2 (citing 21 CFR 1301.43). Here, Registrant did not request a hearing. RFAA, at 2.[1]                                          “A default, unless excused, shall be deemed to constitute a waiver of the [registrant's] right to a hearing and an admission of the factual allegations of the [OSC].” 21 CFR 1301.43(e).                

                    Further, “[i]n the event that a registrant . . . is deemed to be in default . . . DEA may then file a request for final agency action with the Administrator, along with a record to support its request. In such circumstances, the Administrator may enter a default final order pursuant to [21 CFR] § 1316.67.”                     *Id.*                     § 1301.43(f)(1). Here, the Government has requested final agency action based on Registrant's default pursuant to 21 CFR 1301.43(c), (f), 1301.46. RFAA, at 1;                     *see also*21 CFR 1316.67.                

## Findings of Fact

                    The Agency finds that, in light of Registrant's default, the factual allegations in the OSC are admitted. According to the OSC, effective February 21, 2023, the Illinois Department of Financial and Professional Regulation suspended                           ( print page 79309)                        Registrant's Illinois medical license. RFAAX 1, at 1. According to Illinois's online records, of which the Agency takes official notice, Registrant's Illinois medical license remains suspended.[2]                                          Illinois Department of Financial and Professional Regulation License Search,                     *https://online-dfpr.micropact.com/​lookup/​licenselookup.aspx/​*                     (last visited date of signature of this Order). Accordingly, the Agency finds that Registrant is not licensed to practice medicine in Illinois, the state in which he is registered with DEA.                

## Discussion

                    Pursuant to 21 U.S.C. 824(a)(3), the Attorney General is authorized to suspend or revoke a registration issued under 21 U.S.C. 823 “upon a finding that the registrant . . . has had his State license or registration suspended . . . [or] revoked . . . by competent State authority and is no longer authorized by State law to engage in the . . . dispensing of controlled substances.” With respect to a practitioner, DEA has also long held that the possession of authority to dispense controlled substances under the laws of the state in which a practitioner engages in professional practice is a fundamental condition for obtaining and maintaining a practitioner's registration.                     *See, e.g.,**James L. Hooper, D.O.,*76 FR 71371, 71372 (2011),                     *pet. for rev. denied,*                     481 F. App'x 826 (4th Cir. 2012);                     *Frederick Marsh Blanton, D.O.,*43 FR 27616, 27617 (1978).[3] 

                    Pursuant to the Illinois Controlled Substances Act, a practitioner in good faith (“the regular course of professional treatment”) may dispense a controlled substance. 720 Ill. Comp. Stat. 570/312(a), 570/102(u) (2024).[4]                                          A “practitioner” means “a physician licensed to practice medicine in all its branches . . . or other person licensed, registered, or otherwise lawfully permitted by the United States or [Illinois] to distribute, dispense, conduct research with respect to, administer or use in teaching or chemical analysis, a controlled substance in the course of professional practice or research.”                     *Id.*                     570/102(kk).                

Here, the undisputed evidence in the record is that Registrant currently lacks authority to practice medicine in Illinois. As discussed above, an individual must be a licensed practitioner to dispense a controlled substance in Illinois. Thus, because Registrant lacks authority to practice medicine in Illinois, and, therefore, is not authorized to handle controlled substances in Illinois, Registrant is not eligible to maintain a DEA registration. Accordingly, the Agency will order that Registrant's DEA registration be revoked.

## Order

Pursuant to 28 CFR 0.100(b) and the authority vested in me by 21 U.S.C. 824(a), I hereby revoke DEA Certificate of Registration No. AW2016651 issued to Theodore S. Wright Jr., M.D. Further, pursuant to 28 CFR 0.100(b) and the authority vested in me by 21 U.S.C. 823(g)(1), I hereby deny any pending applications of Theodore S. Wright Jr., M.D., to renew or modify this registration, as well as any other pending application of Theodore S. Wright Jr., M.D., for additional registration in Illinois. This Order is effective October 28, 2024.

## Signing Authority

                    This document of the Drug Enforcement Administration was signed on September 19, 2024, by Administrator Anne Milgram. That document with the original signature and date is maintained by DEA. For administrative purposes only, and in compliance with requirements of the Office of the Federal Register, the undersigned DEA Federal Register Liaison Officer has been authorized to sign and submit the document in electronic format for publication, as an official document of DEA. This administrative process in no way alters the legal effect of this document upon publication in the                     **Federal Register**                    .                

Heather Achbach, 

Federal Register Liaison Officer, Drug Enforcement Administration.

# Footnotes

1.                             Based on the Government's submissions in its RFAA dated October 17, 2023, the Agency finds that service of the OSC on Registrant was adequate. Specifically, the included declaration from a DEA Diversion Investigator indicates that on August 31, 2023, Registrant was personally served with the OSC at his registered address. RFAAX 2, at 1;                         *see also id.*                         at 3 (Form DEA-12 signed by Registrant on August 31, 2023).                    
        Back to Citation      

2.                             Under the Administrative Procedure Act, an agency “may take official notice of facts at any stage in a proceeding—even in the final decision.” United States Department of Justice, Attorney General's Manual on the Administrative Procedure Act 80 (1947) (Wm. W. Gaunt & Sons, Inc., Reprint 1979). Pursuant to 5 U.S.C. 556(e), “[w]hen an agency decision rests on official notice of a material fact not appearing in the evidence in the record, a party is entitled, on timely request, to an opportunity to show the contrary.” Accordingly, Registrant may dispute the Agency's finding by filing a properly supported motion for reconsideration of findings of fact within fifteen calendar days of the date of this Order. Any such motion and response shall be filed and served by email to the other party and to Office of the Administrator, Drug Enforcement Administration at                         *dea.addo.attorneys@dea.gov.*
        Back to Citation      

3.                             This rule derives from the text of two provisions of the Controlled Substances Act (CSA). First, Congress defined the term “practitioner” to mean “a physician . . . or other person licensed, registered, or otherwise permitted, by . . . the jurisdiction in which he practices . . . , to distribute, dispense, . . . [or] administer . . . a controlled substance in the course of professional practice.” 21 U.S.C. 802(21). Second, in setting the requirements for obtaining a practitioner's registration, Congress directed that “[t]he Attorney General shall register practitioners . . . if the applicant is authorized to dispense . . . controlled substances under the laws of the State in which he practices.” 21 U.S.C. 823(g)(1). Because Congress has clearly mandated that a practitioner possess state authority in order to be deemed a practitioner under the CSA, DEA has held repeatedly that revocation of a practitioner's registration is the appropriate sanction whenever he is no longer authorized to dispense controlled substances under the laws of the state in which he practices.                         *See, e.g.,**James L. Hooper,*76 FR 71371-72;                         *Sheran Arden Yeates, D.O.,*71 FR 39130, 39131 (2006);                         *Dominick A. Ricci, D.O.,*58 FR 51104, 51105 (1993);                         *Bobby Watts, D.O.,*53 FR 11919, 11920 (1988);                         *Frederick Marsh Blanton,*43 FR 27617.                    
        Back to Citation      

4.                             “Dispense” means “to deliver a controlled substance to an ultimate user or research subject by or pursuant to the lawful order of a prescriber, including the prescribing, administering, packaging, labeling, or compounding necessary to prepare the substance for that delivery.”                         *Id.*                         570/102(p).                    
        Back to Citation      

[FR Doc. 2024-22200 Filed 9-26-24; 8:45 am]

BILLING CODE 4410-09-P